Results 151 to 160 of about 94,068 (259)

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

open access: yesThe Journal of Pathology, EarlyView.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov   +6 more
wiley   +1 more source

Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer. [PDF]

open access: yesCancers (Basel)
Dragoumis D   +27 more
europepmc   +1 more source

Targeting fibrosis in the treatment of lower urinary tract dysfunction

open access: yesThe Journal of Pathology, EarlyView.
Abstract Benign prostatic hyperplasia (BPH) is a widely prevalent age‐associated disease that is the main contributor to lower urinary tract dysfunction (LUTD) in aging men. Although prostate fibrosis has been recognized as a contributor to BPH pathophysiology, there are not any clinically available therapeutics that target this aspect of disease ...
Ajinkya R Limkar   +6 more
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

open access: yesPrecision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik   +4 more
wiley   +1 more source

Safety, efficacy, pharmacokinetics, and mechanisms of novel 10B‐boronophenylalanine combined with a radio‐frequency quadrupole accelerator in boron neutron capture therapy: A preclinical study in head and neck squamous cell carcinoma

open access: yesPrecision Radiation Oncology, EarlyView.
This study demonstrates that the novel 10B‐BPA‐based BNCT system, combined with an RFQ accelerator, effectively targets head and neck squamous cell carcinoma. It induces tumor regression safely and efficiently by triggering DNA damage and activating the ROS/HIF‐1α/NF‐κB pathway, leading to caspase‐3‐mediated apoptosis.
Zhaoyuan Zhang   +13 more
wiley   +1 more source

An Ulcerated Nodule on the Scalp

open access: yes
JEADV Clinical Practice, EarlyView.
Zainab Asghar   +2 more
wiley   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

open access: yesPhytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy